SCHEMBL772459

SCHEMBL772459

CC(CNC(=O)CCCC(=O)N1CCCC2CCCCC21)(c1ccccc1)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.46
RAB9A P51151 3/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
F2 P00734 1/20 0.44
PRSS1 P07477 1/20 0.44
HSD11B1 P28845 3/20 0.42
MEN1 O00255 1/20 0.41
KMT2A Q03164 1/20 0.41
DPP4 P27487 5/20 0.41
DPP8 Q6V1X1 1/20 0.40
HPGD P15428 1/20 0.40
HSD17B1 P14061 1/20 0.39
LMNA P02545 1/20 0.39
NR1H2 P55055 1/20 0.39
NR1H3 Q13133 1/20 0.39
DRD2 P14416 1/20 0.38
DRD4 P21917 1/20 0.38
DUT P33316 2/20 0.38
PREP P48147 1/20 0.38
CHRM2 P08172 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL770291 0.82 GAA (0.56) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL771812 0.81 NPC1 (0.46) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL770751 0.81 DPP4 (0.54) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL771117 0.81 NPC1 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL770456 0.80 MEN1 (0.55) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL770941 0.80 TAAR1 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL771606 0.80 DPP4 (0.47) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL769995 0.80 EPHX2 (0.54) NPC1RAB9AHSD11B1MEN1KMT2A
SCHEMBL15386649 0.79 ASAH1 (0.50) NPC1RAB9ASMN1; SMN2HSD11B1MEN1
SCHEMBL771638 0.79 ASAH1 (0.50) NPC1RAB9ASMN1; SMN2HSD11B1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 97/4885RAB9A 2187/4885SMN1; SMN2 3653/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 NPC1 104/4885RAB9A 2217/4885SMN1; SMN2 3637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.